Shi Xiaoxue, Zheng Jinhua, Ma Jianjun, Wang Zhidong, Sun Wenhua, Li Mingjian, Huang Shen, Hu Shiyu
Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China.
Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Henan University People's Hospital, Zhengzhou, China.
Neurosci Lett. 2022 Jul 13;783:136735. doi: 10.1016/j.neulet.2022.136735. Epub 2022 Jun 13.
Insulin-like growth factor 1 (IGF-1) plays a protective role in Parkinson's disease (PD). To date, studies on the relationship between plasma IGF-1 levels and nonmotor symptoms and brain gray matter volume in PD patients have been rare.
A Siemens automatic chemical analyzer was used to determine plasma IGF-1 levels in 55 healthy controls and 119 PD patients, including those at the early (n = 67) and middle-late (n = 52) stages of the disease. Evaluation of motor symptoms and nonmotor symptoms in PD patients was assessed by the associated scales. Image acquisition in 65 PD patients was performed using a Siemens MAGNETOM Prisma 3 T magnetic resonance imaging (MRI) scanner.
Plasma IGF-1 levels in early-stage PD patients were higher than those in healthy controls, and plasma IGF-1 levels in early-stage PD patients were higher than those in middle-late-stage PD patients. Plasma IGF-1 levels were significantly negatively correlated with anxiety, depression and cognitive dysfunction. Receiver operating characteristic (ROC) curve assessment confirmed that plasma IGF-1 levels had good predictive accuracy for PD with anxiety, depression and cognitive dysfunction. Furthermore, plasma IGF-1 levels were significantly positively correlated with volumes in the insula, caudate and anterior cingulate.
This study shows that plasma IGF-1 levels were correlated with the nonmotor symptoms of anxiety, depression and cognitive dysfunction and the volume in specific brain areas. This is the first report examining the relationships between plasma IGF-1 and clinical manifestations and imaging features in PD patients.
胰岛素样生长因子1（IGF-1）在帕金森病（PD）中发挥保护作用。迄今为止，关于PD患者血浆IGF-1水平与非运动症状及脑灰质体积之间关系的研究很少。
使用西门子自动化学分析仪测定55名健康对照者和119名PD患者的血浆IGF-1水平，其中包括疾病早期（n = 67）和中晚期（n = 52）的患者。通过相关量表评估PD患者的运动症状和非运动症状。65名PD患者使用西门子MAGNETOM Prisma 3T磁共振成像（MRI）扫描仪进行图像采集。
早期PD患者的血浆IGF-1水平高于健康对照者，且早期PD患者的血浆IGF-1水平高于中晚期PD患者。血浆IGF-1水平与焦虑、抑郁和认知功能障碍显著负相关。受试者工作特征（ROC）曲线评估证实，血浆IGF-1水平对伴有焦虑、抑郁和认知功能障碍的PD具有良好的预测准确性。此外，血浆IGF-1水平与岛叶、尾状核和前扣带回的体积显著正相关。
本研究表明，血浆IGF-1水平与焦虑、抑郁和认知功能障碍等非运动症状以及特定脑区的体积相关。这是首篇研究PD患者血浆IGF-1与临床表现及影像学特征之间关系的报告。
